LOGIN  |  REGISTER
Cue Biopharma
Assertio

Stryker launches Steri-Shield 8 personal protection system

March 04, 2025 | Last Trade: US$394.22 9.39 2.44
  • Latest personal protection system offers customizable helmet and three toga choices

PORTAGE, Mich., March 4, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of its Steri-Shield 8 personal protection system, the latest in its personal protective equipment (PPE). Steri-Shield 8 was designed through years of research, testing and collaboration with real-world users.

Steri-Shield 8 lighted helmet and battery.

"Over the last 30 years, we have relentlessly innovated our personal protection system to address the needs of today's professionals and prioritize the safety and well-being of care team members and patients," said Bill Scott, vice president and general manager of Stryker's Orthopaedic Instruments business. "As the personal protection system leader in the market, we're pleased to introduce the Steri-Shield 8 system to further enhance protection and wearability."

The Steri-Shield 8 personal protection system includes a helmet with three points of contact for a customizable fit, a sleeker battery, a more efficient charging station and three toga styles.

Key features include:

  • An intuitively designed helmet with three points of securement for an adjustable fit and a ponytail path to accommodate long-haired users
  • Enhanced visibility, with a brighter helmet light and a 22% wider field of vision than the past generation*
  • A fan design that targets the front and back of users' necks to keep them cool
  • Three toga styles with AAMI level 4 (2012) protection in all critical zones, providing the highest fluid and microbial barrier for healthcare professionals*

For more information, visit: https://www.stryker.com/us/en/orthopaedic-instruments/products/steri-shield-8.html

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

*Stryker internal data

Media Contact:
Beth Sizemore
Sr. Director, Strategic Communications, Instruments
This email address is being protected from spambots. You need JavaScript enabled to view it.

Steri-Shield 8 pullover toga.

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page